Jungki Min

Jungki Min

Auto-generated profile, based on publicly available information

Jungki Min

Department of Biochemistry, Duke University School of Medicine, Durham, North Carolina, United States of America

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2015 in Nature
Verified
Journal Article
Closed access
PDF file
MSMaria A. Schumacher
Maria A. Schumacher
PBPooja Balani
Pooja Balani
JMJungki Min
Jungki Min
NCNaga Babu Chinnam
Naga Babu Chinnam
SHSonja Hansen
Sonja Hansen
RBRichard G. Brennan
Richard G. Brennan

29 August 2003 in FEBS Letters
Verified
Journal Article
Closed access
AMAmy M McGough
Amy M McGough
CSChris J Staiger
Chris J Staiger
JMJung-Ki Min
Jung-Ki Min
KSKaren D Simonetti
Karen D Simonetti

1 October 2013 in Structure
Verified
Journal Article
Closed access
LNLisheng Ni
Lisheng Ni
SLSheng Li
Sheng Li
JYJianzhong Yu
Jianzhong Yu
JMJungki Min
Jungki Min
CBChad A. Brautigam
Chad A. Brautigam
XLXuelian Luo
Xuelian Luo

15 June 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SHSonja Hansen
Sonja Hansen
MVMarin Vulić
Marin Vulić
JMJungki Min
Jungki Min
TYTien-Jui Yen
Tien-Jui Yen
MSMaria A. Schumacher
Maria A. Schumacher
KLKim Lewis
Kim Lewis
Bacterial populations produce antibiotic-tolerant persister cells. A number of recent studies point to the involvement of toxin/antitoxin (TA) modules in persister formation. hipBA is a type II TA module that codes for the HipB antitoxin and the HipA toxin. HipA is an EF-Tu kinase, which causes protein synthesis inhibition and dormancy upon phosphorylation of its substrate. Antitoxins are labile proteins that are degraded by one of the cytosolic ATP-dependent proteases. We followed the rate of HipB degradation in different protease deficient strains and found that HipB was stabilized in a lon- background. These findings were confirmed in an in vitro degradation assay, showing that Lon is the main protease responsible for HipB proteolysis. Moreover, we demonstrated that degradation of HipB is dependent on the presence of an unstructured carboxy-terminal stretch of HipB that encompasses the last 16 amino acid residues. Further, substitution of the conserved carboxy-terminal tryptophan of HipB to alanine or even the complete removal of this 16 residue fragment did not alter the affinity of HipB for hipBA operator DNA or for HipA indicating that the major role of this region of HipB is to control HipB degradation and hence HipA-mediated persistence.

1 April 2001 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
YKYong-Sam Kim
Yong-Sam Kim
JMJung-Ki Min
Jung-Ki Min
DKDonghern Kim
Donghern Kim
JJJin Jung
Jin Jung
ABP57 is an auxin-binding protein that possesses receptor function. In this study, a protocol for ABP57 purification was developed on the basis of cross-reactivity shown between ABP57 and antisera raised against bovine serum albumin, which enabled us to purify ABP57 with a high yield and to further characterize it. ABP57 activates plant plasma membrane H+-ATPase (PM H+-ATPase) via direct interaction. The binding of indole-3-acetic acid (IAA) to the primary binding site on ABP57 caused a marked increase in the affinity of ABP57 for PM H+-ATPase, which was accompanied by a change in ABP57 conformation. Meanwhile, additional IAA binding to the secondary site on ABP57 nullified the initial effect without inducing further conformational change. When ABP57 with IAA occupying only the primary site interacted with PM H+-ATPase, no IAA could access the secondary site. These results suggest that IAA-induced biphasic alteration in the affinity of ABP57 for PM H+-ATPase correlates with a bell-shaped dose response of the enzyme to IAA. There is also a possibility that, whereas the stimulation phase of the response is associated with a conformational change of ABP57, the destimulation phase probably results from hindrance arising directly from the presence of IAA at the secondary site.

17 January 2023 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
NLNicole A. LaHood
Nicole A. LaHood
JMJungki Min
Jungki Min
TKTarun Keswani
Tarun Keswani
CRCrystal M. Richardson
Crystal M. Richardson
KAKwasi Amoako
Kwasi Amoako
SPSarita U. Patil
Sarita U. Patil
In IgE-mediated food allergies, exposure to the allergen activates systemic allergic responses. Oral immunotherapy (OIT) treats food allergies through incremental increases in oral allergen exposure. However, OIT only induces sustained clinical tolerance and decreased basophil sensitivity in a subset of individuals despite increases in circulating allergen-specific IgG in all treated individuals. Therefore, we examined the allergen-specific antibodies from 2 OIT cohorts of patients with sustained and transient responses. Here, we compared antibodies from individuals with sustained or transient responses and discovered specific tolerance-associated conformational epitopes of the immunodominant allergen Ara h 2 recognized by neutralizing antibodies. First, we identified what we believe to be previously unknown conformational, intrahelical epitopes using x-ray crystallography with recombinant antibodies. We then identified epitopes only recognized in sustained tolerance. Finally, antibodies recognizing tolerance-associated epitopes effectively neutralized allergen to suppress IgE-mediated effector cell activation. Our results demonstrate the molecular basis of antibody-mediated protection in IgE-mediated food allergy, by defining how these antibodies disrupt IgE-allergen interactions to prevent allergic reactions. Our approach to studying the structural and functional basis for neutralizing antibodies demonstrates the clinical relevance of specific antibody clones in antibody-mediated tolerance. We anticipate that our findings will form the foundation for treatments of peanut allergy using neutralizing antibodies and hypoallergens.